Heart failure & cardiomyopathies
Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States
Authors' conclusion
HFpEF/HFmrEF is associated with high rates of HF hospitalization and cardiovascular mortality based on contemporary clinical trials in this population.
Study context
- Population
- US patients with symptomatic (NYHA II–IV) heart failure with preserved ejection fraction (HFpEF)/heart failure with mid-range ejection fraction (HFmrEF)simulated cohort
- Outcome
- Clinical outcomes:
- HF hospitalization
- Death
- Follow-up
- 10 years
Methodological detailsMarkov model, inputs derived from phase 3 HFpEF/HFmrEF trials
- Markov model
- Inputs derived from phase 3 HFpEF/HFmrEF trials
Main finding
As reported in the abstract
| Group | Cumulative heart failure (HF) hospitalizations per patient | ≥1 HF hospitalization | CV death | Life expectancy from age 72 | Total cost of care |
|---|---|---|---|---|---|
| Standard of care (SoC) | 0.53 | 37% | 26% | 6.1 years | $123,900 |
Standard of care (SoC)
Cumulative heart failure (HF) hospitalizations per patient0.53
≥1 HF hospitalization37%
CV death26%
Life expectancy from age 726.1 years
Total cost of care$123,900
Original publication
Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States. JACC Adv. Published 24 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →